MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Rocket Pharmaceuticals Inc

Closed

SectorHealthcare

7.42 3.49

Overview

Share price change

24h

Current

Min

7.05

Max

7.49

Key metrics

By Trading Economics

Income

6.4M

-60M

EPS

-0.62

Employees

299

EBITDA

6.4M

-57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+465.28% upside

Dividends

By Dow Jones

Next Earnings

2 May 2025

Market Stats

By TradingEconomics

Market Cap

-304M

765M

Previous open

3.93

Previous close

7.42

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Rocket Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Jun 2024, 14:25 UTC

Major Market Movers

Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi

Peer Comparison

Price change

Rocket Pharmaceuticals Inc Forecast

Price Target

By TipRanks

465.28% upside

12 Months Forecast

Average 42 USD  465.28%

High 55 USD

Low 15 USD

Based on 15 Wall Street analysts offering 12 month price targets forRocket Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

14

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

5.9 / 7.44Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.